Literature DB >> 9462681

Evidence of independent origin of multiple tumors from patients with prostate cancer.

L Cheng1, S Y Song, T G Pretlow, F W Abdul-Karim, H J Kung, D V Dawson, W S Park, Y W Moon, M L Tsai, W M Linehan, M R Emmert-Buck, L A Liotta, Z Zhuang.   

Abstract

BACKGROUND: In men with prostate cancer, the gland usually contains two or more widely separate tumors. A critical issue of prostatic carcinogenesis is whether these multiple tumors are independent in origin. Molecular analysis of microsatellite (i.e., highly repeated, short nucleotide sequences) alterations in the DNA from separate tumors in the same prostate can be used to determine whether or not these separate tumors arise independently.
METHODS: Four microsatellite polymorphic markers (D8S133, D8S136, and D8S137, for a putative tumor suppressor gene on chromosome 8p, and D17S855, for the BRCA1 gene on chromosome 17q) were used to examine the pattern of allelic loss in prostate cancer from 19 patients who had two or more distantly separate tumors (i.e., located on contralateral sides or separated by at least half the anterior-posterior diameter of the prostate). Forty distantly separate tumors were microdissected, DNA samples were prepared from formalin-fixed, paraffin-embedded wholemount prostate tissue section, and the overall frequencies of loss of heterozygosity at the four loci were determined.
RESULTS: The pattern of allelic loss was compatible with independent tumor origin in 15 of 18 informative cases. A random discordant pattern of allelic deletion was observed in distantly separate tumors, whereas the same allele was consistently lost in cells from different regions of the same tumor. For three patients, the results were compatible with either intraglandular dissemination or independent origin of prostate cancer.
CONCLUSIONS: Our data suggest that multiple tumors in some patients with prostate cancer have independent origin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462681     DOI: 10.1093/jnci/90.3.233

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  47 in total

1.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

Review 2.  Integrin clipping: a novel adhesion switch?

Authors:  Manolis C Demetriou; Anne E Cress
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

3.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

4.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

5.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Authors:  Marc Barry; Sven Perner; Francesca Demichelis; Mark A Rubin
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

6.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Authors:  Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

7.  Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

Authors:  Todd B Sheridan; H Ballentine Carter; Wenle Wang; Patricia B Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

8.  Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer.

Authors:  Zhiwei Zhang; Zheng Zhu; Deyong Yang; Weiwei Fan; Jianbo Wang; Xiancheng Li; Xiaochi Chen; Qifeng Wang; Xishuang Song
Journal:  Oncol Lett       Date:  2016-06-10       Impact factor: 2.967

Review 9.  Considerations for patient selection for focal therapy.

Authors:  John F Ward; Louis L Pisters
Journal:  Ther Adv Urol       Date:  2013-12

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.